Evidence map›Paper›PMID 31552620›Full record

ArticleHead and neck pathology2020

Validation of the Brandwein Gensler Risk Model in Patients of Oral Cavity Squamous Cell Carcinoma in North India.

Arun Chaturvedi, Nuzhat Husain, Sanjeev Misra, Vijay Kumar, Sameer Gupta, Naseem Akhtar, Manikandan Lakshmanan, Sudeep Garg, Aditi Arora, Kavitha Jain

Open access · greenAbstract readValidation Study
In one paragraph

Article in Head and neck pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Tumor-host interface in oral squamous cell carcinoma: Impact on nodal metastasis and prognosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021
    Article
  15. Article
  16. Article
  17. Relevance of Tumor Budding and Pattern of Invasion in Oral Squamous Cell Carcinoma.International journal of applied & basic medical research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Arun ChaturvediDepartment of Surgical Oncology, King George's Medical University, Lucknow, India.
Nuzhat HusainDepartment of Pathology, RML Institute of Medical Sciences, Lucknow, India.
Sanjeev MisraDepartment of Surgical Oncology, King George's Medical University, Lucknow, India.
Vijay KumarDepartment of Surgical Oncology, King George's Medical University, Lucknow, India.
Sameer GuptaDepartment of Surgical Oncology, King George's Medical University, Lucknow, India.
Naseem AkhtarDepartment of Surgical Oncology, King George's Medical University, Lucknow, India.
Manikandan LakshmananDepartment of Surgical Oncology, King George's Medical University, Lucknow, India.
Sudeep GargDepartment of Surgical Oncology, King George's Medical University, Lucknow, India.
Aditi AroraDepartment of Pathology, RML Institute of Medical Sciences, Lucknow, India.
Kavitha JainDepartment of Surgical Oncology, King George's Medical University, Lucknow, India. kavithaajain@yahoo.co.in.ORCID http://orcid.org/0000-0002-4134-9829
King George's Medical University · INDr. Ram Manohar Lohia Institute of Medical Sciences · INAll India Institute of Medical Sciences Jodhpur · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

India has one of the highest incidences of oral squamous cell carcinoma (OSCC), with 75,000-80,000 new cases a year. The outcome in early oral cancer is better, but a significant proportion (12-14%) of these patients still relapses and dies due to locoregional or distant recurrences. Several clinicopathological and molecular factors have been used to prognosticate and predict outcomes in these patients of OSCC. The present study aims to validate Brandwein Gensler (BG) risk predictive model in surgically treated OSCC patients in a tertiary care centre in North India. All oral cavity cancer patients, treated in the Department of Surgical Oncology, King George's Medical University, between 2013 and 2017, were reviewed. Patients with histologically diagnosed OSCC, aged > 18 years undergoing primary surgical resection were included in the study. The final histopathological evaluation was done by a dedicated pathologist to categorize patients according to BG model risk categories. This model comprises of three factors, lymphocytic host response, perineural invasion and worst pattern of invasion, scored by the method described by Brandwein Gensler et al. The sum of these scores is used to define low, moderate and high risk categories. The study, conducted during 2013-2017, included 149 patients. Median age was 45 years (range 25-75 years). Tobacco use was noted in 143 patients. Buccal mucosa was the most common site (51%). Surgical margins were clear (> 5 mm) in 97.9% cases. Postoperative radiotherapy was given in 47.7% patients. Locoregional recurrences (LRR) (primary site and neck) were documented in 17 of the 149 patients (11.4%). There was no synchronous or metachronous distant metastasis noted in any of the study patients. Six patients had disease specific mortality. Among the 17 patients with LRR, majority (11) belonged to the high risk category of the BG risk model. Adjuvant radiotherapy had been administered in 10 of these 11 recurrent patients belonging to the high risk category. The Brandwein Gensler risk model is predictive of locoregional recurrences (p = 0.02) for OSCC undergoing primary surgery. It can be used to devise strategies to prevent recurrences or identification of recurrences at an earlier point for salvage. The benefit of further escalation of adjuvant therapy in the high risk category needs further studies, as 90% patients in this group recurred despite complete adjuvant treatment.

Indexed as

AdultAgedFemaleHumansIndiaMaleMiddle AgedMouth NeoplasmsNeoplasm Recurrence, LocalPrognosisRisk FactorsSquamous Cell Carcinoma of Head and NeckAdjuvantOral cavity cancerRecurrenceRisk modelSurgery

Identifiers

PMID31552620
PMCPMC7413965
OpenAlexW2976184334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.